Pneumococcal pneumonia: Update on therapy in the era of antibiotic resistance

Bernard Karnath, Akua Agyeman, Albert Lai

Research output: Contribution to journalArticle

Abstract

The emergence of drug-resistant pneumococci has changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against Streptococcus pneumoniae offer an alternative in the treatment of infection with penicillin-resistant strains. These agents are not recommended as first-fine therapy because of concerns about the development of resistance. Reserve the fluoroquinolones for patients who are allergic to macrorides and β-lactams, have failed to respond to a first-line agent, or have a documented infection with a highly resistant strain. The pneumococcal vaccine is recommended for all persons aged 65 years and older, adults with chronic cardiopulmonary diseases, and immunocompromised persons. Consider revaccination every 6 years in asplenic patients and immunocompromised persons. In addition, vaccination against influenza can help prevent secondary pneumonia and reduce the need for hospitalization.

Original languageEnglish (US)
Pages (from-to)321-326
Number of pages6
JournalConsultant
Volume43
Issue number3
StatePublished - Mar 2003

Fingerprint

Pneumococcal Pneumonia
Microbial Drug Resistance
Fluoroquinolones
Streptococcus pneumoniae
Pneumonia
Secondary Immunization
Lactams
Pneumococcal Vaccines
Immunocompromised Host
Infection
Penicillins
Human Influenza
Vaccination
Hospitalization
Chronic Disease
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pneumococcal pneumonia : Update on therapy in the era of antibiotic resistance. / Karnath, Bernard; Agyeman, Akua; Lai, Albert.

In: Consultant, Vol. 43, No. 3, 03.2003, p. 321-326.

Research output: Contribution to journalArticle

Karnath, Bernard ; Agyeman, Akua ; Lai, Albert. / Pneumococcal pneumonia : Update on therapy in the era of antibiotic resistance. In: Consultant. 2003 ; Vol. 43, No. 3. pp. 321-326.
@article{4758079f1d964af09f12f164c43617f0,
title = "Pneumococcal pneumonia: Update on therapy in the era of antibiotic resistance",
abstract = "The emergence of drug-resistant pneumococci has changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against Streptococcus pneumoniae offer an alternative in the treatment of infection with penicillin-resistant strains. These agents are not recommended as first-fine therapy because of concerns about the development of resistance. Reserve the fluoroquinolones for patients who are allergic to macrorides and β-lactams, have failed to respond to a first-line agent, or have a documented infection with a highly resistant strain. The pneumococcal vaccine is recommended for all persons aged 65 years and older, adults with chronic cardiopulmonary diseases, and immunocompromised persons. Consider revaccination every 6 years in asplenic patients and immunocompromised persons. In addition, vaccination against influenza can help prevent secondary pneumonia and reduce the need for hospitalization.",
author = "Bernard Karnath and Akua Agyeman and Albert Lai",
year = "2003",
month = "3",
language = "English (US)",
volume = "43",
pages = "321--326",
journal = "Consultant",
issn = "0010-7069",
publisher = "Cliggott Publishing Co.",
number = "3",

}

TY - JOUR

T1 - Pneumococcal pneumonia

T2 - Update on therapy in the era of antibiotic resistance

AU - Karnath, Bernard

AU - Agyeman, Akua

AU - Lai, Albert

PY - 2003/3

Y1 - 2003/3

N2 - The emergence of drug-resistant pneumococci has changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against Streptococcus pneumoniae offer an alternative in the treatment of infection with penicillin-resistant strains. These agents are not recommended as first-fine therapy because of concerns about the development of resistance. Reserve the fluoroquinolones for patients who are allergic to macrorides and β-lactams, have failed to respond to a first-line agent, or have a documented infection with a highly resistant strain. The pneumococcal vaccine is recommended for all persons aged 65 years and older, adults with chronic cardiopulmonary diseases, and immunocompromised persons. Consider revaccination every 6 years in asplenic patients and immunocompromised persons. In addition, vaccination against influenza can help prevent secondary pneumonia and reduce the need for hospitalization.

AB - The emergence of drug-resistant pneumococci has changed the empiric treatment of community-acquired pneumonia. Newer fluoroquinolones with activity against Streptococcus pneumoniae offer an alternative in the treatment of infection with penicillin-resistant strains. These agents are not recommended as first-fine therapy because of concerns about the development of resistance. Reserve the fluoroquinolones for patients who are allergic to macrorides and β-lactams, have failed to respond to a first-line agent, or have a documented infection with a highly resistant strain. The pneumococcal vaccine is recommended for all persons aged 65 years and older, adults with chronic cardiopulmonary diseases, and immunocompromised persons. Consider revaccination every 6 years in asplenic patients and immunocompromised persons. In addition, vaccination against influenza can help prevent secondary pneumonia and reduce the need for hospitalization.

UR - http://www.scopus.com/inward/record.url?scp=0037351733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037351733&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037351733

VL - 43

SP - 321

EP - 326

JO - Consultant

JF - Consultant

SN - 0010-7069

IS - 3

ER -